Pyridostigmine in the treatment of adults with severe SARS-CoV-2 infection (PISCO): a randomised, double-blinded, phase 2/3, placebo-controlled trial

Sergio Fragoso-Saavedra, Isaac Núñez, Belem M. Audelo-Cruz, Sarahi Arias-Martínez, Daniel Manzur-Sandoval, Alejandro Quintero-Villegas, H. Benjamín García-González, Sergio L. Carbajal-Morelos, Sergio Ponce de León-Rosales, José Gotés-Palazuelos, José A. Maza-Larrea, Yanink Caro-Vega, Isabella Batina, León Islas-Weinstein, David A. Iruegas-Nunez, Juan J. Calva, Pablo F. Belaunzarán-Zamudio, Juan Sierra-Madero, José C. Crispín, Sergio I. Valdés-Ferrer.

Affiliations:

Plan de Estudios Combinados en Medicina (MD/PhD Program), Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico (S Fragoso-Saavedra MD); Internal Medicine Residency Training Program, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico (I Núñez MD, A Quintero-Villegas MD, HB García-González MD, SL Carbajal-Morelos MD); Departamento de Neurología y Psiquiatría (S Fragoso-Saavedra MD, BM Audelo-Cruz MD, S Arias-Martínez MD, I Batina MD, DA Iruegas-Nunez MD, SI Valdés-Ferrer MD, PhD); Educación Médica (S Ponce de León-Rosales MD); Medicina (J Gotés-Palazuelos MD, MSc); Inmunología y Reumatología (JC Crispín MD, PhD); Infectología (S Fragoso-Saavedra MD, Y Caro-Vega PhD, JJ Calva MD; MSc, J Sierra-Madero MD, SI Valdés-Ferrer MD, PhD) and Patología Experimental (L Islas-Weinstein MD; PhD), Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico; Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico (BM Audelo-Cruz MD); Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico (D Manzur-Sandoval MD, JA Maza-Larrea MD); Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Monterrey, Mexico (DA Iruegas-Nunez MD, JC Crispín MD, PhD); Bethesda, MD, USA (PF Belaunzarán-Zamudio MD, MSc); Center for Biomedical Science, Feinstein Institutes for Medical Research, Manhasset, NY, USA. (SI Valdés-Ferrer MD, PhD).

Address correspondence to: Sergio I. Valdés-Ferrer, Departamento de Neurología y Psiquiatría, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Phone: +52(55)5487-0900, ext. 4177. Email: sergio.valdesf@incmnsz.mx

Summary

Background: Hospitalised patients with severe COVID-19 have an increased risk of developing acute

respiratory distress syndrome (ARDS) and death from severe systemic inflammatory response.

Acetylcholine modulates the acute inflammatory response through a neuro-immune mechanism

known as the inflammatory reflex. Pyridostigmine, an acetylcholine-esterase inhibitor, increases the

half-life of endogenous ACh, reducing lung and systemic inflammation in murine sepsis. This trial

aimed to evaluate whether pyridostigmine could decrease invasive mechanical ventilation (IMV) and

death in patients with severe COVID-19.

Methods: We performed a parallel-group, multicentre, double-blinded, placebo-controlled,

randomised clinical trial in two COVID-19-designated hospitals in Mexico City, Mexico. Adult (≥ 18-

year-old), hospitalised patients with confirmed SARS-CoV-2 infection based on a positive RT-PCR test

in a respiratory specimen, a computed tomography compatible with pneumonia, as well as requiring

supplementary oxygen were included. Patients were randomly assigned (1:1) to receive oral

pyridostigmine (60 mg per day) or placebo for a maximum of 14 days. The intention-to-treat analysis

included all the patients who underwent randomisation. The primary endpoint was the composite

outcome of initiation of IMV and 28-day all-cause mortality. The trial is registered in ClinicalTrials.gov,

NCT04343963.

Findings: Between May 5, 2020, and Jan 29, 2021,188 participants were randomly assigned to

placebo (n=94) or pyridostigmine (n=94). The composite outcome occurred in 22 (23·4%) *vs.* 11

(11·7%) participants, respectively (hazard ratio 0·46, 95% CI 0·22-0·96, *p*=0·03). The most frequent

adverse event was diarrhoea (5 [5·3%] in the pyridostigmine group *vs* 3 [3·2%] in the placebo group).

Most of the adverse events were mild to moderate, with no serious adverse events related to

pyridostigmine.

Interpretation: Our data indicates that the addition of pyridostigmine to standard treatment reduces

significantly the fatality rate among patients hospitalized for severe COVID-19.

Funding: Consejo Nacional de Ciencia y Tecnología, México.

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus

disease 2019 (COVID-19)[1], is a novel pathogen first identified in late 2019 that reached pandemic

proportions within weeks after the first cases were reported[2]. COVID-19 represents a heterogeneous

disease that ranges from asymptomatic to lethal. Patients with severe COVID-19 develop a severe

systemic inflammatory response[3] and acute respiratory distress syndrome[4], that may progress to

multiple-organ failure and death[5,6]. Although the factors that determine the clinical expression of

COVID-19 are not completely understood, an exuberant deregulated inflammatory response plays a

central pathogenic role in patients with severe disease. In concordance, pharmacological strategies

aimed at reducing inflammation have been able to moderately reduce disease outcomes.

Dexamethasone, reduced mortality among patients requiring supplementary oxygen or ventilatory

support. However, its use was accompanied by important and frequent adverse effects such as

hyperglycaemia, psychosis, and gastrointestinal hemorrhage[7]. Tocilizumab, a recombinant humanised

anti-interleukin (IL)-6 receptor monoclonal antibody, reduced the need for mechanical ventilation, as

well as mortality, in patients with severe COVID-19, regardless of the degree of respiratory support

needed[8]. Finally, remdesivir, an antiviral, alone or in combination with baricitinib, a selective inhibitor of

Janus kinases 1 and 2, accelerated recovery and reduced in-hospital stay[9,10]. These three

approaches may have increased survival rates, but severe COVID-19 remains an unsolved problem,

in particular in countries with low vaccine coverage.

The central nervous system regulates the inflammatory response via the release of acetylcholine by

the vagus nerve, reducing the production of inflammatory mediators, through the *inflammatory reflex*[11].

Choline-acetyltransferase (ChAT)-expressing T cells modulate inflammation via *in situ* release of

acetylcholine[12] and this effect is critical in reducing viremia in animal models of viral infection[13].

Pyridostigmine, an acetylcholinesterase inhibitor (i-ACh-e), increases acetylcholine (ACh) half-life by

inhibiting its peripheral degradation. Pyridostigmine is used for the symptomatic treatment of

myasthenia gravis[14] and as pre-exposure prophylaxis for nerve gas poisoning[15]. In human

immunodeficiency virus (HIV)-1 infection, pyridostigmine modulates T-cell activation and reduces

circulating inflammatory markers[16–18]. Recent experimental evidence indicates that, in murine

lipopolysaccharide (LPS)-induced systemic inflammation, pyridostigmine reduces lung neutrophil

recruitment, as well as levels of tumour necrosis factor and IL-6 in the bronchioalveolar lavage[19].

Pyridostigmine has not yet been evaluated as immuno-modulator in acute severe human inflammatory

conditions; nonetheless, indirect clinical and experimental evidence suggests that pyridostigmine may

be effective in reducing the inflammation in patients with COVID-19.

Our main aim was to evaluate the efficacy of pyridostigmine as an adjunct therapy to reduce the

incidence of critical illness or death in hospitalized adults with severe COVID-19.

METHODS

Study design and participants

We performed a double-blinded, placebo-controlled, parallel group randomised, bicentric clinical trial

at Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), and Instituto

Nacional de Cardiología Ignacio Chávez (INCICh), two COVID-19-designated Hospitals in Mexico

City, Mexico. Adult (≥18-year-old) hospitalised patients with confirmed SARS-CoV-2 infection,

documented by a positive RT-PCR test for SARS-CoV-2 RNA in a respiratory specimen

(nasopharyngeal or nasal swab), an imaging study compatible with pneumonia, and at least one risk

factor for requiring IMV or dying (Figure 1), were invited to participate. The full list of inclusion,

exclusion and elimination criteria has been published[20].

All participants provided written informed consent. The clinical study protocol was approved by the

Ethics in Human Research Committees of both study centres (approval identifier: INF-3323-20-21-1).

Randomisation and masking

Patients were randomised in a 1:1 ratio, with a parallel assignment and unstratified block-

randomisation approach using a publicly available online resource (www.randomizer.org) to receive

pyridostigmine or placebo besides standard medical treatment. Preparing, packing, masking, and

labelling active and placebo pills, as well as overseeing drug dispensing was performed by trained

pharmacy staff at both study centres. Pyridostigmine and placebo pills were unidentifiable from one

another. Participants were enrolled and assigned to treatment by investigators. Throughout the study,

participants, site staff and investigators were masked to the treatment allocation until completion of the

intervention and follow-up phases. There was no formalised evaluation of masking.

Procedures and outcomes

The primary outcome was a composite of invasive mechanical ventilation (IMV) or death in the 28

days following randomisation (Fig. 1), and frequency of specific adverse events. Prespecified

secondary outcomes included: (a) the length of in-hospital days after randomisation; (b) hospital

discharge by day-28; (c) among those who required IMV, the number of days with, and the survival

rate after IMV; (d) failure to complete treatment as expected due to adverse events (other than the

primary composite outcome).

Participants were allocated (1:1 ratio) to receive, in addition to standard medical treatment, either oral

pyridostigmine at a dose of 60 mg/day P.O. or a matching placebo (pharmaceutical-grade starch) until

the occurrence of (a) any of the prespecified outcomes, (b) hospital discharge, or (c) 14 in-hospital

days. We collected demographic information from participants at baseline, including age, sex, and

comorbidities (including diabetes mellitus, hypertension, obesity, cardiovascular disease, lung

disease, or other chronic medical conditions). Participants already discharged from the hospital by day

28, including those who were transferred to another facility, were contacted by telephone to assess

their vital and functional status.

Adverse events (AEs) were collected using data obtained from the medical health records of each

study participant. The events were evaluated and coded using the Medical Dictionary and Regulatory

Activities (MedDRA) version 24·0 browser and the severity of the AEs was assessed by the National

Cancer Institute Common Terminology Criteria for Adverse Events, version 5·0.

Although not used throughout the study, unblinding was allowed in case of severe adverse events at

the request of either the treating group of physicians or the external Data and Safety Monitoring Board

(DSMB). The study was conducted in two parts, as already described[20]: a phase 2 aimed at

determining safety (5 May to 4 July 2020), followed by a phase 3 aimed at evaluating the effect -or

lack thereof- of pyridostigmine in patients with severe COVID-19 (5th July 2020, to 30th January 2021).

Participants in both phases were included in the analyses of outcomes.

Statistical analysis

The trial was planned and approved in March 2020, shortly after the first case of COVID-19 was

diagnosed in Mexico. At that time, we relied on limited information about clinical outcomes in these

patients. Thus, we calculated a sample size of 436 participants considering an event rate of 25% in

the control group, a 10% absolute reduction (40% relative reduction) in the primary outcome as

clinically significant, and a power of 80% to detect a difference in the primary outcome using a two-

sided significance level of $\alpha=0\cdot05$[20]. However, we pre-stipulated that the sample size would be

adjusted according to interim analyses. The first participant was recruited on May 5th, 2020. The

DSMB performed an interim analysis after the first 44 participants (22 per group, 10% of the calculated

sample) to evaluate safety on July 4th, 2020; a second interim analysis was conducted on December

7th, 2020 including 28-day outcomes on 100 participants (50 per group). Due to an observed

difference in the primary outcome between groups (still blinded to investigators, but unblinded to the

DSMB), as well as difficulty recruiting new participants due to a reduction in eligible patients and a

swell in competing studies, we decided to stop the trial after 188 participants had been recruited (94 in

each group). Considering the same $\alpha=0\cdot05$, we recalculated the statistical power of the obtained

sample with the observed difference between groups (an absolute reduction of 11·7% and relative

reduction of 50%), which resulted in ~85%.

We conducted an intention-to-treat analysis for the primary outcome that included all the patients who

underwent randomisation. As secondary outcomes, we assessed between-group differences of

mechanical ventilation and death with or without IMV. Patients that had not developed an outcome by

day 28 were censored at day 29. The magnitude of the effect of pyridostigmine on the primary

outcome was estimated with a hazard ratio (HR) and its 95% confidence interval (CI) calculated with

Cox proportional hazard model and the difference between groups was compared with log-rank test,

as were IMV, and death with or without IMV, and discharge home although these secondary outcomes

were not pre-specified in the study protocol. We built Kaplan Meier survival curves to plot the

cumulative incidence of the primary outcome up to day-28. Statistical analysis was conducted with

Prism GraphPad software, version 9·1·0 (GraphPad Software, San Diego, CA), and R version 4·0·0.

This trial is registered in ClinicalTrials.gov, NCT04343963.

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation,

or writing of the report.

RESULTS

Patients

Between May 5, 2020, and Jan 29, 2021, we assessed for eligibility 334 patients, of whom 201

accepted to participate; of those, thirteen patients were excluded for the following reasons: five

withdrew consent after signing but before randomisation; four were transferred to a different facility

before randomisation; three required IMV before randomisation, and one was diagnosed with lung

cancer (one of our exclusion criteria) during the initial assessment, therefore withdrawn from the study

before randomisation. In total, 188 participants underwent randomisation, 94 in each group, all of

whom received at least one dose of the assigned intervention. Enrolment and randomisation are

shown in **Figure 1**. Baseline demographic and clinical characteristics were balanced between groups

(**Table 1**).

The median age of the patients was 52 years (interquartile range [IQR], 44 to 64 years), and 59·6 %

were male. The most common pre-existing conditions at enrolment were diabetes and hypertension

(**Table 1**). The imbalance of obesity proportion between groups appeared to be clinically relevant

(53·2% *vs.* 33%, affecting predominantly the pyridostigmine group), so we performed an X^2 test which

also showed a statistically significant difference (*p=0·005*). There were no relevant differences in the

rest of the baseline characteristics between groups, including the number of patients who received

dexamethasone or tocilizumab as part of in-hospital medical management (**Table 1**). All participants

were hypoxemic and received supplementary oxygen as part of in-patient management. The median

interval from symptom onset to randomisation was 10 days (IQR, 9 to 12 days). The median interval

from hospital admission to randomisation was 2 days (IQR, 1 to 3 days). Dexamethasone was

administered to 140 participants (69 on the pyridostigmine group and 71 on the placebo group).

Tocilizumab was administered to 10 participants (5 on the pyridostigmine group, and 5 on the placebo

group). None of the participants received Remdesivir.

Primary outcome

Thirty-three participants met the primary outcome by day 28; 11 (11·7%) in the pyridostigmine group

and 22 (23·4%) in the control group (HR 0·47, 95% CI 0·23-0·95, p=0·03) (**Figure 2)**. IMV was

initiated in 6 (6·4%) patients in the pyridostigmine group and 7 (7·5%) in the placebo group (HR 0·81,

95%CI 0·27-2·42, p=0·7) **(Figure 3a-b)**. The median duration of IMV was 15 days (IQR, 10 to 23) in

the pyridostigmine group and 17 days (IQR, 7 to 39) in the placebo group. The survival rate after IMV

was 66·7% (four patients) in the pyridostigmine group and 42·9% (three patients) in the placebo group.

Secondary outcomes

A total of 26 patients died by day 28, 7 in the pyridostigmine group and 19 in the placebo group (HR

0·33, 95%CI 0·14-0·81, p=0·01) **(Figure 3c)**. All of the deaths in the pyridostigmine group occurred in

the study centre while three in the placebo group happened after the patients had been transferred to

another centre. The median duration of in-hospital stay after randomisation (censored at day 29) was

5 days (IQR, 3 to 10 days) in the pyridostigmine group and 5 days (IQR, 3 to 8 days) in the placebo

group. The twenty-eight-day hospital discharge rate was 90·4% (85 patients) in the pyridostigmine

group and 75·5% (71 patients) in the control group (Table 2 and Fig. 3). As expected, the use of

dexamethasone was adequately balanced between study groups (69 in the pyridostigmine group and

71 in the placebo group). In the placebo group, the composite primary endpoint occurred more

commonly among patients that did not receive dexamethasone (35% *vs.* 20%, respectively). In

contrast, in the pyridostigmine group, an opposite trend was observed (8% *vs.*13%, respectively).

However, the study was not designed, nor has the power, to address drug synergism.

We collected and analysed 83 AEs throughout the study. Overall, 45 (47·9%) patients of the

pyridostigmine group and 38 (40·4%) of the placebo group had at least one adverse drug reaction.

The rate and severity of AEs were similar between both groups (Supplemental Tables 1-3).

One hundred and sixty-six (88·3%) participants received experimental treatment (i.e., pyridostigmine

or placebo) as assigned during their in-hospital stay; 22 (11·7%) discontinued treatment early, nine

(9·5%) in the pyridostigmine group, and 13 (13·8%) in the placebo group. Two participants in each

group discontinued trial medication due to an adverse event other than the principal outcome: one

patient presented nausea and one mild abdominal pain in the pyridostigmine group (known adverse

effects of pyridostigmine), and in the placebo group one patient had pyrosis and one presented

diarrhoea. The remaining patients discontinued trial medication after being transferred to another

facility **(Figure 1)**. Drug adherence was supervised by a physician or nurse, and each administration

was confirmed in the electronic records; therefore, among the 166 participants who received

medication as assigned, adherence was 100%.

Finally, as obesity status differed between study groups, we performed a sensitivity analysis with a

Cox proportional hazards model adjusted for obesity status. We excluded 10 patients (four from the

pyridostigmine group and six from the control group) that had no information on obesity status (of

which only one had a primary outcome) for this sensitivity analysis, obtaining an adjusted HR of 0·42

(95% CI 0·19-0·91, p=0.05) for the primary outcome, 0·78 (95%CI 0·24-2·54, p=0·3) for IMV, and 0·32

(95%CI 0·13-0·77, p=0·03) for death.

DISCUSSION

Here, we show that added to standard care, pyridostigmine is associated with decreased IMV and

mortality in patients hospitalized for severe COVID-19. This was driven by a decrease in all-cause

mortality in the pyridostigmine group compared to that of the placebo group (by 12·7 percentage

points). IMV was an infrequent outcome, which explains the lack of difference when analysing this

outcome by itself. Also, the adjunct use of pyridostigmine increased the probability of being discharged

from the hospital alive within 28 days.

Early reports estimated mortality rates as elevated as 49% for hospitalized patients with severe

COVID-19[21]. Although the in-hospital mortality rate has been declining throughout the pandemic,

recent studies still show rates ranging from 20 to over 40%[22–25]. For instance, the risk of death still

exceeded 20% in the dexamethasone and tocilizumab arms of the RECOVERY trial, being the only

two treatments that have shown a reduction in mortality[7,24]. Similarly, in the placebo group we

observed a 28-day mortality of 20.21%, but a majority had received dexamethasone as part of the

standard of care, indicating that, without further intervention, in-hospital mortality of severe COVID-19

remains high. The severity and mortality of COVID-19 are mediated by the development of an

uncontrolled inflammatory response to infection; elevated levels of proinflammatory cytokines and

other immune mediators have been associated with multiorgan failure due to endothelial damage and

tissue injury[4,6]. Hence, finding novel immunomodulatory strategies represents a promising strategy to

reduce the severity and mortality of COVID-19. That, along with the repurposing of drugs with well-

characterized safety profiles and readily available production lines, might lead to faster development of

anti-COVID-19 therapies if proven efficacious in well-designed, randomised clinical trials.

In mammals, the central nervous system has mechanisms to control the inflammatory response.

During inflammatory states, the vagus nerve can inhibit the synthesis and release of inflammatory

cytokines, thereby reducing both local damage and mortality secondary to severe systemic

inflammation in murine models as diverse as sepsis, ischemia, and reperfusion damage, or obesity[26–

[29]. The vagus nerve can be stimulated electrically and chemically. Chemical stimulation using

cholinergic agonists has shown promising effects in murine and cellular models of inflammation[29,30].

Acetylcholine esterase inhibitors (i-ACh-e) are a family of drugs used regularly by millions of patients,

including older adults with Alzheimer's disease and other dementias, as well as patients with

myasthenia gravis and dysautonomia[14,31–34]. These drugs inhibit the enzymatic degradation of

endogenous ACh, resulting in greater bioavailability and, therefore, increasing the possibility of binding

to both nicotinic and muscarinic receptors. In addition to the approved uses of i-ACh-e in human

pathology, there is evidence in various murine models of their efficacy in experimental sepsis and

severe inflammatory response[19,27,28,30], suggesting that i-ACh-e drugs may exert a potential

immunomodulatory effect in patients with severe systemic inflammatory response syndrome.

Regarding safety concerns, at the used dose of pyridostigmine (60 mg/day), the rate of adverse

events we observed was 47.9% -none severe- and not different from the observed rate in the placebo

group (40.4%).

The reduction in mortality in patients with severe COVID-19 who received pyridostigmine may be due

to an immunomodulatory effect, however, its precise biological effect in this novel disease remains to

be studied. Different immunomodulatory strategies have been tested that have sought to selectively

inhibit the biological activity of certain pro-inflammatory cytokines, such as IL-6[35]; however, the global

inhibition of several of them by pharmacologically stimulating the inflammatory reflex could be more

effective, which is the effect sought with the administration of pyridostigmine. We are currently working

in understanding the mechanism behind our observed effect.

Our study has important limitations. The originally planned sample size could not be achieved. Still, a

significant difference was observed because of a greater than expected effect. Also, some patients

requiring IMV could probably not receive it because of either, a pre-existing living will; last-minute

patient (or proxy) refusal of intubation; or, intermittently throughout the study period, lack of availability

of critical care beds[22,23]. Our primary outcome included initiation, but not necessarily the requirement,

of IMV. This is reflected by the fact that the bulk of the primary outcome was due to deaths among

participants who did not receive IMV, most likely related to lack of critical care space. Thus, our results

may not be generalizable to settings that do not have this problem. While most baseline

characteristics were evenly balanced between groups, obesity (a known predictor of adverse

outcomes in COVID-19) was randomly more prevalent in the pyridostigmine group; this imbalance that

in principle plays against pyridostigmine strengthens our observed outcomes. As a proof-of-concept,

this study needs to be replicated or refuted in independent clinical trials. Also, at this point, our results

cannot be extrapolated to patients with less severe disease, or those already receiving IMV, without

prior verification in clinical trials. Finally, medium-term outcomes (90 days) will be reported at a later

time point.

The strengths of the study include that it is a double-blinded, placebo-controlled, multicentric

randomised clinical trial that evaluated a therapeutic intervention that is inexpensive, has a positive

pharmacological profile, is safe, and is widely available as a generic drug. The demographics of our

study population, including age and comorbid conditions, are representative of a large group of the

underserved population worldwide (particularly across the Americas), a population in urgent need of

safe, effective, life-saving, and affordable treatments for severe COVID-19.

In conclusion, we present evidence to support the use of pyridostigmine as an add-on treatment to

standard medical care in patients hospitalized for severe COVID-19. Our data indicate that this

inexpensive and readily available drug may significantly reduce mortality without imposing relevant

adverse effects.

Contributors

JCC, PFBZ, JSM and SIVF designed the study. SFS, SIVF, and IN wrote the manuscript. JCC, JSM

and JJC contributed to the writing of the article. SFS did the block randomisation. SFS, BMAC, SAM,

DMS, IN, HBGG, AQV, SLCM and SIVF contributed to the recruitment of participants. JAML and JGP

evaluated the safety of the pharmacological intervention. SFS, BMAC, DMS, DAIN, IB, and LIW

contributed to data gathering and entry. SFS, IN, SIVF analysed all data. PFBZ, YCV, and SPdeLR

provided additional statistical support. SFS, IN, and SIVF accessed and verified the trial data. All

authors approved the submission of this article.

Data sharing

De-identified individual participant data and all protocol documents can be provided to others upon

reasonable request on approval of a written request to the corresponding author.

Declaration of interests

SI Valdés-Ferrer via Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán appears as

inventor for a repurpose patent for the use of pyridostigmine in COVID-19. If granted, we aim to

release the patent to the public domain.

Acknowledgements: This study was funded by Consejo Nacional de Ciencia y Tecnología, Mexico

(COVID-19 Fund [F0005-2020-01]; grant 311790), to SIV-F]. The authors are grateful to Kevin J.

Tracey, M.D., for his insight and suggestions that positively impacted this manuscript; to Claudia

Quiñones, B.Ch. and, Elia Criollo-Mora, B.Ch. for preparing, packing, masking, labelling, and

dispensing treatments; to Dr Virginia Pascual-Ramos for providing ethical and statistical

recommendations throughout the study; and to Dr Florencia Rosetti and the Immunopathology Lab,

INCMNSZ for their logistic support. Lastly, the authors wish to dedicate this manuscript to all medical

and surgical residents and fellows across the world for their generous and selfless work during the

COVID-19 pandemic. We understand that this is not the kind of residency training you dreamed of, but

your work has, time and again, made a difference and every day you make us all proud.

Table 1. Clinical and demographical characteristics of patients at baseline.

Variables	All (N=188)	Pyridostigmine (N=94)	Placebo (N=94)
Sex - no. (%)	-	-	-
Male	112 (59·6)	56 (59·6)	56 (59·6)
Female	76 (40·4)	38 (40·4)	38 (40·4)
Age	-	-	-
Median (IQR) - yr	52 (44-64)	51 (43-63)	54 (46-66)
Previous coexisting disease - no. (%)	-	-	-
Diabetes	68 (36·2)	33 (35·1)	35 (37·2)
Hypertension	66 (35·1)	33 (35·1)	33 (35·1)
Heart disease	4 (2·1)	2 (2·1)	2 (2·1)
Chronic lung disease	8 (4·3)	6 (6·4)	2 (2·1)
Obesity**	81 (43·1)	50 (53·2)	31 (33)
Median BMI (IQR) – kg/m^2**	29 (26·5-33)	30·25 (26·5-33·4)	28·1 (26·5-31·45)
Median time (IQR) from symptom onset to randomisation - days	10 (9-12)	10 (8-11)	10 (9-13)
Median time (IQR) from admission to randomisation – days	2 (1-3)	2 (1-2)	2 (1-3)
Other immunomodulators used by medical team – no. (%)	-	-	-
Dexamethasone	140 (74·5)	69 (73·4)	71 (75·5)
Tocilizumab	10 (5·3)	5 (5·3)	5 (5·3)

337 ****BMI information was not available for 10 patients, four in the pyridostigmine group and six in**

338 **the placebo group.**

341   **Table 2. Primary and secondary outcomes by day 28.**

Outcomes	All (N=188)	Pyridostigmine (N=94)	Placebo (N=94)	HR (95% CI)	P-value
Primary outcome					
Invasive mechanical ventilation or death – no. (%)	33 (17·5%)	11 (11·7%)	22 (23·4%)	0·46 (0·23-0·95)	0·03
Secondary outcomes					
Invasive mechanical ventilation – no. (%)	13 (6·9%)	6 (6·3%)	7 (7·4%)	0·81 (0·27-2·42)	0·7
Median time (IQR) in ICU with invasive mechanical ventilation - days	17 (11-23)	15 (15-21)	17 (12-30)	-	-
Survival after IMV — no. (%)	7 (53·8)	4 (66%)	3 (42·9)	-	-
Death - no. (%)	26 (13·8%)	7 (7·4%)	19 (20·2%)	0·33 (0·14-0·81)	0·01
*Median time (IQR) from randomisation to discharge home — days	5 (3-9)	5 (3-10)	5 (3-8)	-	-
Discharge home by day 28 – no. (%)	156 (82·9)	85 (90·4)	71 (75·5)	1·13 (0·82-1·55)	0·4
Adverse events - no. (%)	83 (44·1)	45 (47·9)	38 (40·4)	-	
Failure to complete treatment due to adverse effects — no. (%)	4 (2)	2 (2)	2 (2)	-	-

*For time to discharge home in patients that were transferred, the time from randomisation until

discharge home from the hospital that they were transferred to was used. Two patients did not have

this information available but were discharged home alive. For them, the date of transfer was used.

Patients that were still in the hospital on day 28 were censored on day 29.

FIGURE LEGENDS

Figure 1. Enrolment and randomisation.

Figure 2. Time to Mechanical Ventilation or Death by Day 28.

Figure 3. Time to Mechanical Ventilation, Death or Discharge Home by Day 28 as Separate

Outcomes. A) IMV as the primary outcome; B) death as the primary outcome; and, C) Discharge

home as the primary outcome. Hazard ratios were calculated with Cox proportional hazards models

and p-values were obtained with a log-rank test. In the case of IMV as the primary outcome, deaths

without IMV were censored. In the case of death as the primary outcome, IMV was not considered.

References

1 Zhu N, Zhang D, Wang W, *et al.* A Novel Coronavirus from Patients with Pneumonia in China,

2019. *N Engl J Med* 2020; **382**: 727–33.

2 Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/map.html (accessed

May 15, 2021).

3 Xu Z, Shi L, Wang Y, *et al.* Pathological findings of COVID-19 associated with acute respiratory

distress syndrome. *Lancet Respir Med* 2020; **8**: 420–2.

4 Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel coronavirus

in Wuhan, China. *Lancet* 2020; **395**: 497–506.

5 Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19

based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020; **46**:

846–8.

6 Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider

cytokine storm syndromes and immunosuppression. *Lancet* 2020; **395**: 1033–4.

7 Horby P, Lim WS, Emberson J, *et al.* Dexamethasone in Hospitalized Patients with Covid-19. *N*

Engl J Med 2021; **384**: 693–704.

8 RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19

(RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. *Lancet*

2021; **397**: 1637–45.

9 Beigel JH, Tomashek KM, Dodd LE, *et al.* Remdesivir for the Treatment of Covid-19 — Final

Report. *N Engl J Med* 2020; **383**: 1813–26.

10 Kalil AC, Patterson TF, Mehta AK, *et al.* Baricitinib plus Remdesivir for Hospitalized Adults with

Covid-19. *N Engl J Med* 2021; **384**: 795–807.

Borovikova L V., Ivanova S, Zhang M, *et al.* Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature* 2000; **405**: 458–62.

Rosas-Ballina M, Olofsson PS, Ochani M, *et al.* Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit. *Science (80-)* 2011; **334**. DOI:10.1126/science.1209985.

Cox MA, Duncan GS, Lin GHY, *et al.* Choline acetyltransferase–expressing T cells are required to control chronic viral infection. *Science (80-)* 2019; **363**: 639–44.

Gilhus NE, Verschuuren JJ. Myasthenia gravis: Subgroup classification and therapeutic strategies. *Lancet Neurol* 2015; **14**: 1023–36.

Keeler JR, Hurst CG, Dunn MA. Pyridostigmine Used as a Nerve Agent Pretreatment Under Wartime Conditions. *JAMA J Am Med Assoc* 1991; **266**: 693–5.

Valdés-Ferrer SI, Crispín JC, Belaunzarán PF, Cantú-Brito CG, Sierra-Madero J, Alcocer-Varela J. Acetylcholine-esterase inhibitor pyridostigmine decreases T cell overactivation in patients infected by HIV. *AIDS Res Hum Retroviruses* 2009; **25**. DOI:10.1089/aid.2008.0257.

Valdés-Ferrer SI, Crispín JC, Belaunzarán-Zamudio PF, *et al.* Add-on Pyridostigmine enhances CD4+ T-cell recovery in HIV-1-infected immunological non-responders: A proof-of-concept study. *Front Immunol* 2017; **8**: 1–6.

Robinson-Papp J, Nmashie A, Pedowitz E, *et al.* The effect of pyridostigmine on small intestinal bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic neuropathies. *J Neurovirol* 2019; **25**: 551–9.

Bricher Choque PN, Vieira RP, Ulloa L, *et al.* The Cholinergic Drug Pyridostigmine Alleviates Inflammation During LPS-Induced Acute Respiratory Distress Syndrome . Front. Pharmacol. . 2021; **12**: 966.

Fragoso-Saavedra S, Iruegas-Nunez DA, Quintero-Villegas A, *et al.* A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the

403   efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical

404   ventilation in adults with severe SARS-CoV-2 inf. *BMC Infect Dis* 2020; **20**: 765.

405 21 Wu Z, McGoogan J. Characteristics of and important lessons from the coronavirus disease

406   2019(COVID-19) outbreak in China. *Jama* 2020; **2019**: 10.1001/jama.2020.2648.

407 22 Rossman H, Meir T, Somer J, *et al.* Hospital load and increased COVID-19 reñated mortality in

408   Israel. *Nat Commun* 2021; **12**: 1–7.

409 23 Olivas-Martínez A, Cárdenas-Fragoso JL, Jiménez JV, *et al.* In-hospital mortality from severe

410   COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact

411   of hospital saturation. *PLoS One* 2021; **16**: e0245772.

412 24 de Souza FSH, Hojo-Souza NS, Batista BD de O, da Silva CM, Guidoni DL. On the analysis of

413   mortality risk factors for hospitalized COVID-19 patients: A data-driven study using the major

414   Brazilian database. *PLoS One* 2021; **16**: e0248580.

415 25 Núñez I, Priego-Ranero ÁA, García-González HB, *et al.* Common hematological values predict

416   unfavorable outcomes in hospitalized COVID-19 patients. *Clin Immunol* 2021; **225**: 108682.

417 26 Yeboah MM, Xue X, Duan B, *et al.* Cholinergic agonists attenuate renal ischemia-reperfusion

418   injury in rats. *Kidney Int* 2008; **74**: 62–9.

419 27 Satapathy SK, Ochani M, Dancho M, *et al.* Galantamine alleviates inflammation and other

420   obesity-associated complications in high-fat diet-fed mice. *Mol Med* 2011; **17**.

421   DOI:10.2119/molmed.2011.00083.

422 28 Zaghloul N, Addorisio ME, Silverman HA, *et al.* Forebrain cholinergic dysfunction and systemic

423   and brain inflammation in murine sepsis survivors. *Front Immunol* 2017; **8**.

424   DOI:10.3389/fimmu.2017.01673.

425 29 Lehner KR, Silverman HA, Addorisio ME, *et al.* Forebrain cholinergic signaling regulates innate

426   immune responses and inflammation. *Front Immunol* 2019; **10**: 1–11.

30   Rosas-Ballina M, Valdés-Ferrer SI, Dancho ME, *et al.* Xanomeline suppresses excessive pro-

inflammatory cytokine responses through neural signal-mediated pathways and improves

survival in lethal inflammation. *Brain Behav Immun* 2015; **44**: 19–27.

31   Mayeux R. Clinical practice. Early Alzheimer's disease. *N Engl J Med* 2010; **362**: 2194–201.

32   Querfurth HW, Laferla FM. Alzheimer's Disease. *N Engl J Med* 2018; **326**: 329–44.

33   O'Brien JT, Thomas A. Vascular dementia. *Lancet* 2015; **386**: 1698–706.

34   Singer W, Sandroni P, Opfer-Gehrking TL, *et al.* Pyridostigmine treatment trial in neurogenic

orthostatic hypotension. *Arch Neurol* 2006; **63**: 513–8.

35   Salama C, Han J, Yau L, *et al.* Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.

N Engl J Med 2021; **384**: 20–30.

Figure 1. Enrollment and randomization

No. at risk

Placebo	94	80	75	72	72
Pyridostigmine	94	88	85	84	83

No. at risk					
Placebo	94	84	81	77	75
Pyridostigmine	94	93	89	88	87

No. at risk

Placebo	94	31	13	6	4
Pyridostigmine	94	36	13	9	2